RecruitingPhase 2NCT07400952

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Sponsor

Glaukos Corporation

Enrollment

100 participants

Start Date

Dec 23, 2025

Study Type

INTERVENTIONAL

Conditions

Keratoconus

Summary

Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GLK-221 Ophthalmic Solution and a drug called Placebo Ophthalmic Solution for people with keratoconus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGLK-221 Ophthalmic Solution

GLK-221 Ophthalmic Solution administered twice daily to both eyes

DRUGPlacebo Ophthalmic Solution

Placebo Ophthalmic Solution administered twice daily to both eyes

Locations(1)

Glaukos Clinical Study Site

Westerville, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07400952

Related Trials

A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

NCT07780890

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

NCT076295571 location